Green Valley
China green lights first novel Alzheimer’s therapy since 2003
November 4, 2019Sales and Marketing Alzheimer's, China, Green Valley, Oligomannate, pharma
Shanghai Green Valley Pharmaceuticals has announced that its therapy Oligomannate (GV-971) has secured marketing approval from China’s National Medical Products Administration (NMPA) …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
